Eudaimonia Partners, LLC Biogen Inc. Transaction History

Eudaimonia Partners, LLC

$416 Million
Q1 2024

A detailed history of Eudaimonia Partners, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Eudaimonia Partners, LLC holds 1,722 shares of BIIB stock, worth $252,221. This represents 0.09% of its overall portfolio holdings.

Number of Shares

1,722

Previous 1,722 -0.0%

Holding current value

$252,221

Previous $445,000 16.63%

% of portfolio

0.09%

Previous 0.12%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$222.59 - $267.94 $14,690 - $17,684	-66 Reduced 3.69%	1,722 $445,000
Q3 2023 Oct 24, 2023	SELL	$253.3 - $285.89 $842,475 - $950,870	-3,326 Reduced 65.04%	1,788 $459,000
Q2 2023 Jul 19, 2023	BUY	$275.25 - $318.06 $845,568 - $977,080	3,072 Added 150.44%	5,114 $1.46 Million
Q4 2022 Jan 24, 2023	SELL	$252.44 - $306.72 $5,048 - $6,134	-20 Reduced 0.97%	2,042 $0
Q3 2022 Nov 03, 2022	SELL	$194.69 - $268.46 $2,336 - $3,221	-12 Reduced 0.58%	2,062 $551,000
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $47,473 - $59,814	245 Added 13.4%	2,074 $437,000
Q3 2021 Oct 25, 2021	BUY	$282.99 - $369.05 $121,685 - $158,691	430 Added 30.74%	1,829 $518,000
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $1,295 - $2,073	5 Added 0.36%	1,399 $484,000
Q4 2020 Feb 18, 2021	BUY	$236.26 - $355.63 $3,071 - $4,623	13 Added 0.94%	1,394 $341,000
Q3 2020 Nov 23, 2020	BUY	$264.77 - $305.71 $182,161 - $210,328	688 Added 99.28%	1,381 $392,000
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $157,273 - $181,591	-594 Reduced 46.15%	693 $31,000
Q1 2020 May 05, 2020	BUY	$268.85 - $341.04 $9,678 - $12,277	36 Added 2.88%	1,287 $407,000
Q4 2019 May 05, 2020	BUY	$220.06 - $304.07 $275,295 - $380,391	1,251 New	1,251 $371,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eudaimonia Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eudaimonia Partners, LLC with notifications on news.

Account

Eudaimonia Partners, LLC Biogen Inc. Transaction History